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Introduction
Hydrops fetalis is defined as excessive fluid accumulation or edema 
in at least 2 fetal compartments. Nonimmune hydrops fetalis is the 
cause in more than 85% of cases, of which 15% have been report-
ed to have a lymphatic-related abnormality (1). In 20% of nonim-
mune hydrops fetalis cases, the cause is not known. Lymphatic-
related (nonimmune) hydrops fetalis (LRHF) has been included 
in a subgroup of primary lymphedemas under the umbrella term 
generalized lymphatic dysplasia (GLD) by Connell et al. (2). In this 
classification, GLD was defined as lymphedema associated with 
systemic or visceral involvement (including hydrops fetalis), even 
if the lymphedema was not widespread. The GLD group includes 
patients with a widespread developmental abnormality of the lym-
phatic system, often presenting prenatally with hydrothoraces or 
nonimmune hydrops fetalis.
Hennekam syndrome (OMIM 235510) is an example of a GLD 
that is inherited in an autosomal recessive manner. Mutations in 
collagen and calcium binding EGF domains 1 (CCBE1) and FAT 
atypical cadherin 4 (FAT4) have been identified as causal (3–5). 
Another recessively inherited form of GLD with a high incidence 
of LRHF has recently been reported as caused by mutations in 
piezo-type mechanosensitive ion channel component 1 (PIEZO1) 
(6), adding to the genetic heterogeneity of the GLD group.
We have recently ascertained 2 families with a history of non-
immune hydrops and postnatal lymphatic dysfunction, but with a 
pattern suggestive of autosomal dominant inheritance and with 
sporadic occurrence in one of the families. We have identified 
heterozygous inactivating mutations in the kinase domain of Eph 
receptor B4 (EPHB4) as causative for this condition. This suggests 
not only that LRHF/GLD is genetically heterogeneous, but also 
that it should be considered in both dominant and recessive forms. 
The importance of EPHB4 for lymphatic vascular development is 
further supported by analysis of a genetic mouse model with lym-
phatic endothelial-specific deletion of Ephb4.
Results
Genetic analysis of LRHF identifies causative mutations in EPHB4. We 
report 2 multigenerational families (one from Norway [GLDNOR] 
and one from the UK [GLDUK]) (Figure 1). Clinical findings in these 
families included antenatal nonimmune hydrops fetalis or bilater-
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filter criterion, and MIER2 was the only gene that fulfilled that (Fig-
ure 1A). However, the MIER2 variant (NM_017550.1: c.865C>T, 
p.Arg289Trp) has been reported as a SNP (rs148482834), with a 
heterozygous genotype observed at a frequency of 0.001.
Meanwhile, an independent study of a GLDNOR family was 
undertaken. In this family, the condition initially appeared to be 
sporadic in monozygotic twins (GLDNOR:II.2 and (GLDNOR:II.3), 
who both had subcutaneous edema at birth that resolved in infan-
cy (Table 1). GLDNOR:II.3 required ventilation and thoracentesis 
for bilateral chylothoraces. Both sisters had sons with nonimmune 
hydrops. One died at 1.5 days of age; the other was moribund in 
the neonatal period, but the edema eventually resolved. Both 
sons also had an ASD. Three genes (protein tyrosine phosphatase, 
non-receptor type 11 [PTPN11], forkhead box C2 [FOXC2], and 
VEGFR3) were ruled out in GLDNOR:II.2 by Sanger sequencing, and 
a high-resolution microarray comparative genomic hybridization 
(CGH) (Affymetrix 6.0) was normal in GLDNOR:II.3. When analyz-
ing the WES data, the only gene to fulfil an autosomal dominant 
model with de novo occurrence was EPHB4. Sanger sequencing 
of additional family members showed all affected family mem-
bers carried the variant (c.2345T>G, p.Ile782Ser) (Figure 1B). 
GLDNOR:II.2 and GLDNOR:II.3 were both found to be mosaic for this 
variant, and GLDNOR:II.2 had a lower mutation load than her twin 
sister, GLDNOR:II.3, consistent with her milder neonatal presen-
tation (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI85794DS1).
As MIER2 had shown perfect cosegregation in GLDUK, the 
WES data of GLDNOR:III.5 was scrutinized, but no variants were 
found in MIER2, and the coverage was found to be of sufficient 
al hydrothoraces and neonatal chylothoraces of variable severity 
(Table 1) as well as a high number of first trimester miscarriages 
(GLDNOR). The nonimmune hydrops fetalis is associated with a 
high mortality, but babies surviving the neonatal period improve 
with time, with spontaneous resolution of the hydrops and pleural 
effusions. Only 1 (GLDUK:I.2) of 5 adults had developed peripheral 
edema of the lower extremities in adolescence (Figure 2), but 3 of 
the 5 adults (GLDNOR:II.2, GLDNOR:II.3 and GLDUK:I.2) had vari-
cose veins. Although GLDUK:II.2 and GLDNOR:II.2 had no clinical 
evidence of peripheral lymphedema at the time of this writing, 
lymphoscintigraphy showed mild bilateral impairment of lymph 
drainage with retention of tracer in the lower limbs in both. In 
addition, GLDUK:II.2 had an atrial septal defect (ASD), diaphrag-
matic hernia, and cystic hygroma at birth. There appeared to be an 
association with ASD in both families (n = 7).
Sanger sequencing identified no pathogenic variants in the 
genes known to be associated with congenital primary lymphedema 
(i.e., CCBE1, VEGFR3, and VEGFC) in the UK proband (GLDUK:I.2). 
Whole-exome sequencing (WES) was performed on the family to 
identify pathogenic variants. When filtering the WES data of the 
UK family for variants in genes known to have relevance to the 
lymphatic system and lymphangiogenesis, an unreported variant 
(NM_004444.4: c.2216G>A, p.Arg739Glu) in EPHB4 was identi-
fied. Initially, it was thought that the variant did not fully cosegregate 
with the disorder status in the family (Figure 1A), as 2 clinically unaf-
fected family members were found to carry the variant (GLDUK:II.4 
and GLDUK:III.2). Neither of these presented with hydrops fetalis, 
but both were later diagnosed with an ASD. The next step of the 
analysis was to apply a specific autosomal dominant inheritance 
Figure 1. Mutations in EPHB4 cause LRHF. (A) Pedigree 
of GLDUK family. (B) Pedigree of GLDNOR family. Stars 
indicate which samples have been exome sequenced. 
Genotypes indicated by minus signs (–) represent the 
WT allele, and plus signs represent (+) the mutant 
allele. Top row of genotypes in GLDUK genogram shows 
EPHB4, and bottom row of genotypes shows MIER2. 
Triangles, first trimester miscarriages; IUD, intrauterine 
death. GLDNOR:III.3 had trisomy 18.
Downloaded from http://www.jci.org on August 12, 2016.   http://dx.doi.org/10.1172/JCI85794
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
3 0 8 2 jci.org   Volume 126   Number 8   August 2016
possibility that the mutations were interfering with the phosphory-
lation state of the WT protein, different ratios of WT and mutant 
proteins were cotransfected and phosphorylation of the receptor 
analyzed as described above. Results showed no dominant nega-
tive effect, as phosphorylation of the total receptor decreased 
when increasing amounts of mutated receptor were cotransfected 
(Figure 3B). Furthermore, Ephrin B2–dependent EPHB4 activa-
tion was evaluated in lymphatic endothelial cells (LECs) after 
expression of Myc-DDK–tagged EPHB4. To distinguish phosphor-
ylation levels of Myc-DDK–tagged exogenous expressed WT and 
mutant EPHB4 from endogenous expressed WT EPHB4, an anti-
DDK antibody was used for the immunoprecipitation and isola-
tion of only the overexpressed forms of Myc-DDK–tagged EPHB4. 
Ephrin B2 treatment increased phosphorylation levels of WT Myc-
DDK–tagged EPHB4, but not mutant proteins (Figure 4), confirm-
ing the negative effect of both mutations on the receptor activity 
after ligand stimulation in LECs.
depth and quality. For good measure, GLDNOR:III.5 was also 
screened by Sanger sequencing for all exons of MIER2; still, no 
variant was identified. Neither EPHB4 variants had been previ-
ously reported in public databases or in 900 in-house controls, 
and it was therefore concluded that mutations in EPHB4 were the 
likely cause of the LRHF/GLD phenotype seen in these 2 families 
despite the variable expression observed.
LRHF-associated mutations lead to inactive EPHB4 kinase. 
EPHB4 binds the transmembrane Ephrin B2. Binding of Ephrin B2 
to EPHB4 stimulates phosphorylation and activates downstream 
signaling cascades (7, 8). The 2 EPHB4 mutations (p.Arg739Glu 
and p.Ile782Ser) occur at highly conserved residues located in 
the tyrosine kinase domain of the EPHB4 protein (Supplemental 
Figure 2 and Supplemental Figure 3A). Moreover, p.Arg739Glu is 
located within the catalytic loop HRD (His-Arg-Asp) motif, also 
highly conserved in many tyrosine kinases (Supplemental Figure 
3B). To investigate the effect of the mutations identified in the 
patients with LRHF, corresponding expression constructs for WT 
and mutant proteins by site-directed mutagenesis were generated 
and analyzed for their phosphorylation activity after transient 
transfection in HEK293T cells. The tyrosine phosphorylation lev-
els of WT, p.Arg739Glu, and p.Ile782Ser mutants were analyzed 
by immunoprecipitation and Western blotting with anti-EPHB4 
and anti–p-tyrosine–specific antibodies. Mutant proteins showed 
no phosphorylation (Figure 3A), suggesting that both mutations 
alter EPHB4 signaling in patients with LRHF/GLD. To test the 
Table 1. Clinical features of family members carrying EPHB4 mutations
Family GLDNOR GLDUK
ID II.2A II.3A III.5 III.9 I.2 II.2 II.4 II.6 II.7 III.1 III.2
Sex F F M M M F F M F M M
Age at last follow-up (yr) 37 37 NA 6 55 30 24 NA NA 8 4
NT at 11/12 wk (mm) (normal < 3 mm) \ \ 2.1 1.8 \ \ \ 3 3.8 2.8 \
Fetal hydrops diagnosed (wk) \ \ 28 28 – + – 20 20 22 –
Extent of hydrops \ \ PE, SC,  
TC × 3
PE, As, SC,  
TC × 4
NA PE, As, SC NA PE, As, 
SC, PC
PE, As, SC PE,SC NA
Gestation at birth (wk) 34 34 30 30 36 34 38 34 IUD 26 32 40
Systemic involvement An RD, CT, An CT CT, An – CT, As – CT, As NA CT –
Peripheral swelling at birth BL, RA T, Fa + + – + – + NA – –
Spontaneous resolution of all swellings + + ND 1.5 d + NA + NA ND 21 d NA + NA
ASD – – + + + + small ASD/PFO – – + multiple ASDs
Persistent peripheral edema – – NA – BL at 15 yr – – NA NA – –
Varicose veins + + NA – + – – NA NA \ \
AMonozygotic twins. As, ascites; An, anemia; BL, bilateral lower limb; CT, chylothoraces; Fa, facial edema; F, female; IUD, intrauterine death; M, male; 
ND, neonatal death; NT, nuchal translucency scan; PC, pericardial effusions; PE, pleural effusions; PFO, patent foramen ovale; RA, right arm edema; RD, 
respiratory distress; SC, subcutaneous edema; T, truncal; TC, thoracocentesis in utero; \, not recorded; –, no; +, yes.
Figure 2. Imaging of the lymphatic system in LRHF. Anterior view of 
lower limb lymphoscintigraphy 2 hours after injection with radionuclide. 
(A) GLDUK:I.2, rerouting through skin and superficial tissues in the right 
leg and markedly reduced transport in the left leg. (B) GLDUK:II.4, normal 
uptake of tracer in the lymph nodes in the groin area, but with some 
rerouting in the calves (seen as the dark shading; arrows). (C) Unaffected 
subject with symmetrical transport of radionuclide within collecting lymph 
vessels in the leg.
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Ephb4 is required for the formation of lymphovenous and lym-
phatic valves. Previous studies have shown that between E10.5 
and E13.5, formation of specialized lymphovenous valves (LVVs) 
occurs at the connection sites between the primordial thoracic 
duct (pTD) and the cardinal vein (refs. 14–16 and Figure 6A). It was 
therefore reasoned that edema in Ephb4 mutants might be due to 
defective LVVs leading to inefficient lymph drainage. To investi-
gate this, we induced Cre recombination in the developing LVVs in 
Ephb4fl/fl Prox1-CreERT2 R26-mTmG embryos by 4-OHT treatment 
between E10.5 and E12.5. Analysis of immunostained transverse 
vibratome sections of E13.5 control embryos showed preferential 
and efficient targeting of the dual LVVs by the Prox1-CreERT2 trans-
gene, while pTD endothelium exhibited mosaic labeling (Figure 
6B). Control LVVs (11 out of 11) consisted of 2 well-defined leaflets 
extending to the lumen of the cardinal vein (Figure 6, C and D, and 
Supplemental Video 1). In contrast, the majority of EPHB4-defi-
cient LVVs (9 out of 13) did not show extended leaflets, but instead 
consisted of abnormal clusters of GFP+ cells (Figure 6, C and D, 
and Supplemental Video 2).
Interestingly, studies using a function-blocking antibody 
and a chemical genetic approach showed that EPHB4 kinase 
signaling regulates lymphatic valve formation (11), while genetic 
EPHB4 deficiency in mice results in subcutaneous edema and abnor-
mal lymphatic development. Ephrin B2/EPHB4 signaling is critically 
required for the development of the cardiovascular system during 
early embryogenesis (9, 10). Ephrin B2 and EPHB4 are also essen-
tial for lymphatic vessel remodeling and valve formation during late 
embryonic and early postnatal development (11, 12), but whether 
they have an earlier role in lymphatic vessel morphogenesis that 
could explain Ephb4 loss of function–induced LRHF/GLD in humans 
is not known. Whole-mount immunofluorescence analysis con-
firmed the previously reported venous and lymphatic endothelial- 
specific expression of EPHB4 in embryonic skin and mesenteries 
(Supplemental Figure 4, A and B). To assess the potential contribu-
tion of lymphatic endothelial EPHB4 loss of function to LRHF/GLD, 
we deleted Ephb4 specifically in the lymphatic vasculature using 
tamoxifen-inducible Prox1-CreERT2 mice crossed with a conditional 
Ephb4fl line (Figure 5A and Supplemental Figure 5). The mice were 
further crossed with the R26-mTmG double reporter to monitor Cre 
activity and to label gene-deleted cells with GFP (Ephb4fl/fl Prox1-
CreERT2 R26-mTmG mice, referred to here as Ephb4 mutants). 
Ephb4 deletion was induced from the earliest stage of lymphatic 
development by administration of 4-hydroxytamoxifen (4-OHT) 
for 5 consecutive days starting at E10.5 (Figure 5A). At E15.5, a high 
proportion of mutant embryos showed subcutaneous edema (Fig-
ure 5, B and C). In addition, a proportion of dermal lymphatic ves-
sels contained blood in 71% of edematous mutant embryos (n = 14), 
but not in nonedematous mutants (n = 5) or in control embryos (n = 
20) (Figure 5C and data not shown). Whole-mount immunofluores-
cence of the skin revealed tortuous and dilated dermal lymphatic 
vessels in the Ephb4 mutants (Figure 5C). Notably, abnormal vessel 
morphology was also observed in vessels that showed a low contri-
bution of GFP+ (i.e., Ephb4-deficient cells) (Figure 5C), suggesting 
that edema and/or blood filling of lymphatic vessels secondarily 
caused vessel dilation. In support of a non–cell-autonomous effect 
of early embryonic deletion of Ephb4 on dermal lymphatic vascula-
ture, inactivation of Ephb4 from E12.5, when dermal lymphatic ves-
sel formation begins (ref. 13 and Figure 5A), resulted in normal vas-
culature despite efficient gene targeting (Figure 5D). These results 
suggest E10–E12 as a critical time-window for EPHB4 function dur-
ing lymphatic development.
Figure 3. Effect of p.Arg739Glu and p.Ile782Ser 
mutations on EPHB4 tyrosine phosphorylation 
in HEK293T cells. (A) HEK293T cells were trans-
fected with expression plasmids for EPHB4 WT and 
p.Arg739Glu and p.Ile782Ser mutants. Receptor 
phosphorylation was analyzed by immunoprecipita-
tion and Western blotting using anti–p-tyrosine 
(p-Tyr, upper panel) and EPHB4 (lower panel) anti-
bodies. The positions of molecular mass markers (in 
kDa) are indicated to the right of the gels. (B) EPHB4 
WT and p.Arg739Glu and p.Ile782Ser mutants were 
cotransfected into HEK293T cells in different ratios 
of WT to mutant plasmid. Receptor phosphorylation 
was analyzed as above. One representative experi-
ment (n = 3) is shown.
Figure 4. Effect of p.Arg739Glu and p.Ile782Ser mutations on EPHB4 
tyrosine phosphorylation in LECs after Ephrin B2 stimulation. LECs were 
transfected with expression plasmids for Myc-DDK–tagged EPHB4 WT and 
p.Arg739Glu and p.Ile782Ser mutants. The cells were stimulated with 1 μg/
ml clustered Ephrin B2/Fc (EB2/Fc) or Fc alone. Receptor phosphorylation 
was analyzed by immunoprecipitation with anti-DDK antibody and West-
ern blotting using anti–p-tyrosine (upper panel) and EPHB4 (lower panel) 
antibodies. The positions of molecular mass markers (in kDa) are indicated 
to the right of the gels. One representative experiment (n = 2) is shown.
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lymphatic phenotype in humans that can be classified as LRHF/
GLD. However, this phenotype shows highly variable expression. 
Some individuals present with severe in utero swelling, which may 
cause perinatal demise (or fully resolve to become completely 
asymptomatic), others with no edema but only an ASD. This 
phenotype can be distinguished from the majority of Hennekam 
syndrome cases, in which the swelling presents in the antenatal 
period but persists throughout life (3–5). The large number of mis-
carriages in GLDNOR may well be related to this disorder. In this 
regard, it is of interest that EPHB4 and Ephrin B2 have been shown 
to be instrumental in human placental development (18). Invasive 
cytotrophoblasts use the EPHB4 expression on veins to ensure 
that migration of these cells into EPHB4-expressing uterine veins 
is limited and instead biased toward the arterial side of the circula-
tion (19). Expression of EPHB4 at half the levels normally encoun-
tered may disturb the complex migration patterns seen in the pro-
cess of placentation. A failure of the invasive cytotrophoblasts to 
take on an arterial phenotype is suspected as leading to the loss 
of pregnancy during the late first or early second trimester (19). 
studies have demonstrated an important function for its ligand, 
Ephrin B2, in the formation of both lymphatic and venous valves 
(12, 17). Using our genetic loss-of-function model, we confirmed 
the essential role of EPHB4 in lymphatic valve morphogenesis. 
Deletion of Ephb4 during embryonic valve formation led to a 
complete absence of valves that form in control mesenteries by 
E18.5 by LECs expressing high levels of PROX1 (Supplemental 
Figure 4C). In addition, early postnatal deletion of Ephb4 led to 
a complete loss of lymphatic valves (Supplemental Figure 4D). 
These results demonstrate a critical role of Ephb4 in the forma-
tion and early postnatal maintenance of lymphatic valves and 
highlight conserved mechanisms regulating the formation of 
valves at different anatomical sites.
Discussion
This study identifies the EPHB4 receptor tyrosine kinase as a criti-
cal regulator of early lymphatic vessel development and a caus-
ative gene for LRHF and primary lymphedema. We have shown 
here that kinase-inactivating mutations in EPHB4 can produce a 
Figure 5. Early embryonic deletion of Ephb4 leads to subcutaneous edema and abnormal dermal lymphatic vasculature. (A) Schematic of the transgenes 
and 4-OHT administration (Cre induction; red arrowheads) schedule used for Ephb4 deletion in the lymphatic vasculature. Timing of primitive lymphatic ves-
sel formation and time point for analysis are indicated. PLLV, peripheral longitudinal lymphatic vessel; LV, lymphatic vessel. (B) Edema in E15.5 control and 
Ephb4 mutant embryos after different 4-OHT treatments. P values determined by Fisher’s exact test. (C and D) Left panels: E15.5 Ephb4fl/+ and Ephb4fl/fl  
Prox1-CreERT2 R26-mTmG embryos. Most mutants treated with 4-OHT at E10.5–E14.5 showed subcutaneous edema (white arrowhead) and blood-filled lym-
phatic vessels (black arrowheads). Boxed area indicates the area of the skin imaged on the right. Right panels: whole-mount immunofluorescence of E15.5 
thoracic skin for NRP2 (red) and GFP (green) to stain lymphatic vessels and gene-targeted cells, respectively. Scale bars: 200 μm (C and D).
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Perinatal deaths were also of a higher frequency in the autosomal 
recessive form of LRHF/GLD caused by PIEZO1 mutations but, in 
this condition, were probably related to the hydrops fetalis (6).
Two GLDUK family members (GLDUK:II.4 and her son, 
GLDUK:III.2) carry the variant, but have no clinical history of pre- 
or postnatal swelling. On lymphoscintigraphy (GLDUK:II.4), quan-
tification showed entirely normal levels of transport of lymph 
within the legs, but imaging was suggestive of rerouting through 
skin and superficial tissues rather than a main lymphatic tract as 
seen in the control (Figure 2B). She had a small ASD and, interest-
ingly, her son had large, multiple ASDs requiring surgical closure. 
Variable expression has been observed in other primary lymph-
edemas, e.g., PIEZO1-related LRHF/GLD (6).
Like other forms of GLD (4, 6), this condition presents ante-
natally with nonimmune hydrops or pleural effusions. The swell-
ing may completely resolve with no residual lymphatic phenotype, 
which is similar to observations in the recently identified PIEZO1-
related GLD (6). However, the report of 1 affected individual with 
bilateral lower limb edema (GLDUK:I.2) with abnormal lymph scans 
suggests that there may be residual, lymphatic weakness in the sur-
vivors. Further studies will be needed to investigate the specific 
nature and extent of the lymphatic dysfunction in these patients.
LEC-specific deletion of Ephb4 in mouse embryos led to subcu-
taneous edema and abnormal lymphatic vessel morphology, thus 
recapitulating aspects of the human LRHF phenotype. Temporal 
analysis of EPHB4 function demonstrated a critical requirement 
of EPHB4 during early stages of lymphatic development. Specifi-
cally, we found that EPHB4 regulates the formation of LVVs that 
are critical for efficient lymphatic function by maintaining unidi-
rectional flow of lymph into blood (14, 20, 21). We additionally con-
firmed the previously reported critical role of EPHB4 in both for-
mation and maintenance of lymphatic valves (11). Lymphatic valve 
defects are, however, an unlikely cause of in utero swelling due to 
their late embryonic development (22, 23). We postulate, therefore, 
that defective LVV formation, caused by the lack of EPHB4, could 
contribute to the LRHF seen in the GLDNOR and GLDUK patients. In 
agreement with this, defective LVVs were recently demonstrated in 
mouse models of primary lymphedemas caused by loss of function 
of FOXC2, connexin 37, and GATA2 (16, 24).
Edema in the mouse embryos lacking EPHB4 specifically in 
the lymphatic endothelia appears to be milder than that observed 
in the patients, suggesting that defective LVVs may only partially 
explain human LRHF/GLD. It is well known that EPHB4 is also 
expressed in venous and capillary endothelium (9, 10), and there-
fore, the impact of the mutations on the venous system needs to 
be considered. In accordance with this hypothesis, some of the 
patients (GLDNOR:II.2 and GLDNOR:II.3; GLDUK:I.2) showed vari-
cose veins, which would be consistent with a valve defect in the 
venous system and would support the contribution of vascular 
deficiency to the observed phenotype. Together with the varicose 
veins, the ASD observed in the patients could also be an important 
part of this phenotype. Both have been reported in lymphedema 
distichiasis syndrome with a frequency of approximately 7% 
(ASDs) (25) and 100% (varicose veins) (26).
Kinase activity is critical for EPHB4 forward signaling in 
lymphatic endothelia (11). Our in vitro data show that EPHB4 
mutants carrying the LRHF-associated mutations p.Arg739Glu 
and p.Ile782Ser are kinase dead, but do not have a dominant 
negative effect on WT protein. In contrast, VEGFR3 mutants in 
Milroy disease have a slower turnover (27), which may affect the 
signaling capacity of the WT tyrosine kinase receptor due to accu-
mulation of mutant receptors on the cell surface. Unlike typical 
Figure 6. Early embryonic deletion of Ephb4 leads to a failure 
of LVV formation. (A) Schematic representation of LVV forma-
tion. CV, cardinal vein; A, artery. Adapted with permission from 
Developmental Biology (ref. 16; Creative Commons user license 
available at http://www.sciencedirect.com/science/article/pii/
S0012160615301032). (B) Whole-mount immunofluorescence of 
a transverse section of E13.5 Ephb4+/+ Prox1-CreERT2 R26-mTmG 
embryo for indicated proteins. GFP shows efficient Cre-mediated 
recombination in the LVV that extends to the lumen of the 
cardinal vein (arrow). (C) Whole-mount immunofluorescence of 
E13.5 LVVs showing extension of the valve leaflets to the lumen 
of the cardinal vein (arrow) in control (upper panel, n = 11 out of 11) 
but not in Ephb4 mutant (Ephb4 mut) embryo (lower panel, n = 
9 out of 13). (D) Quantification of LVV morphology in control and 
Ephb4 mutant embryos. Normal, elongated leaflets; abnormal, 
no leaflets. P value determined by Fisher’s exact test. Scale bars: 
50 μm (B); 25 μm (C).
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receptor tyrosine kinases that dimerize upon ligand stimulation, 
Eph receptors form higher order clusters, with cluster size being 
an important determinant of the quality and strength of cellular 
response (28, 29). Inclusion of a kinase-dead receptor may thus 
significantly weaken the signaling strength of higher order clus-
ters and thereby alter cellular responses. EPHB2 receptor–medi-
ated endocytosis requires the kinase activity of the receptor (30), 
so kinase-dead EPHB4 could also show defective endocytosis, 
influencing clustering dynamics and cellular responses. Further 
studies will aim to investigate those and other functional conse-
quences of the LRHF/GLD-associated mutations.
In conclusion, we report on kinase-inactivating EPHB4 muta-
tions in 11 individuals from 2 extended family pedigrees present-
ing with a phenotypic spectrum from severe, lethal nonimmune 
hydrops to ASD only. The inheritance pattern is typical of autoso-
mal dominant inheritance with variable expression. Using a genet-
ic mouse model, we have further shown that Ephb4 deficiency in 
lymphatic endothelium leads to defective LVVs, which may criti-
cally contribute to edema formation in LRHF/GLD patients. This 
is the first report, to our knowledge, of a human phenotype associ-
ated with EPHB4 mutations and also, we believe, the first report of 
an autosomal dominant form of LRHF.
Methods
Exome sequencing. For GLDUK, sequencing libraries were made follow-
ing the protocol from Roche/Nimblegen’s SeqCap EZ Exome Library 
v2.0 kit. The libraries were then sequenced on HiSeq2000 (Illumina) 
machines. Sequence reads were aligned to the reference genome 
(hg19) using Novoalign (Novocraft Technologies). Duplicate reads, 
resulting from PCR clonality or optical duplicates, and reads mapping 
to multiple locations were excluded from downstream analysis. Depth 
and breadth of sequence coverage were calculated with custom scripts 
and the BedTools package (31).
All variants were annotated using a custom annotation pipeline. 
Single-nucleotide substitutions and small indel variants were identi-
fied and quality filtered within the SamTools software package (32) and 
in-house software tools (33). Variants were annotated with respect to 
genes and transcripts with the Annovar tool (34). Variants were filtered 
for novelty by comparing them with dbSNP135 and 1000 Genomes 
SNP calls and with variants identified in 900 control exomes (primar-
ily of European origin), which were sequenced and analyzed by the 
same method. Summary statistics for the exome sequencing are given 
in Supplemental Tables 1 and 2. Analysis of the exome-variant profiles 
was performed under a model of a rare autosomal dominant disorder; 
this model required one previously unobserved heterozygous variant 
for all affected individuals.
For GLDNOR, the sequencing analysis was performed using the 
SOLID 5500xl platform (Life Technologies). Exon sequences were 
enriched by SureSelect Human All Exon v5 (Agilent Technologies), 
which targets approximately 21,500 human genes, covering a total of 
50 Mb of genomic sequence. Read alignment and variant calling were 
performed with Lifescope v1.3 software. All variants were annotated 
using a custom annotation pipeline. Variants from the exome were fil-
tered for known variants in dbSNP, intronic and UTR variants, synon-
ymous variants, and variants in our in-house database. Variants with 
fewer than 5 variation reads were also omitted. Summary statistics for 
the exome sequencing are given in Supplemental Table 3.
Confirmation sequencing. Samples of available family members were 
analyzed by Sanger sequencing. Primers were designed for the coding 
regions and associated splice sites for exons 13 and 14 of EPHB4 and all 
exons of MIER2 using Primer3 software (35) or ExonPrimer (https://
www.helmholtz-muenchen.de/). Primer sequences are listed in Supple-
mental Table 4. PCR products were sequenced using BigDye Termi-
nator v1.1 and v3.1 chemistry (Life Technologies) and an ABI3130xla 
Genetic Analyzer or 3730 DNA analyzer (Life Technologies). Sequenc-
ing traces were visually inspected in Finch TV v1.4 (Geospiza Inc.) and 
SeqScape Software v2.5 (Life Technologies).
The twins in GLDNOR were also examined for mosaicism by Sanger 
sequencing on DNA extracted directly from blood (new sample), 
urine, saliva, and skin biopsy (fibroblasts).
The variants from the 2 families have been submitted to the Leiden 
Open Variation Database (LOVD3) (genomic variants 0000095140 
[c.2216G>A; p.(Arg739Gln)] and 0000095141 [c.2345T>G; 
p.(Ile782Ser)]; http://databases.lovd.nl/shared/genes/EPHB4).
Site-directed mutagenesis of EPHB4 constructs. The human EPHB4 
mammalian expression plasmids pCMV6-XL6-EPHB4 (SC117357) 
and Myc-DDK–tagged pCMV6-Entry-EPHB4 (RC208559) were 
obtained from OriGene and used as templates for site-directed muta-
genesis using the QuikChange II XL Site-Directed Mutagenesis Kit 
(Agilent). All primers were designed using QuikChange Primer Design 
(Agilent) and are listed in Supplemental Table 5. All constructs were 
verified by DNA sequencing.
Cell culture and transfection. HEK293T cells (provided by Tris 
McKay, St. George’s University of London) were maintained in 
DMEM supplemented with 10% FBS. Transfection of HEK293T cells 
was performed with GeneJuice Transfection Reagent (Merk) follow-
ing the manufacturer’s protocol; 6 × 105 cells/well were seeded in 
6-well plates the day before transfection, and then they were trans-
fected with 3 μl GeneJuice and 1 μg of DNA. Human dermal LECs 
(C-12217) were obtained from PromoCell and maintained in supple-
mented endothelial cell growth medium MV2 (C-22022, PromoCell) 
containing recombinant human VEGF-C (2179-VC-025, R&D Sys-
tems). Transfection of LECs was performed with Viromer YELLOW 
(VY-01LB-01, Lipocalyx) following the manufacturer’s recommen-
dations. 2 × 105 cells/well were seeded in fibronectin-coated (F1141, 
Sigma-Aldrich) 6-well plates the day before transfection and then 
transfected with 1 μg of DNA. For both cell types, lysates were col-
lected 24 hours after transfection and subjected to immunoprecipita-
tion and Western blot analysis.
Ligand activation of EPHB4 receptor. Ephrin B2/Fc (7397-EB-050, 
R&D Systems) or Fc fragment alone (CSB-NP005401h, Stratech) 
was clustered by incubation with a goat anti-human IgG Fc antibody 
(40C-CR2022G-FIT, Stratech) at a 1:2 ratio for 1 hour at 4°C. Eighteen 
hours after transfection, LECs were serum starved for 6 hours and 
then treated with 1 μg/ml clustered Ephrin B2/Fc or Fc alone for 30 
minutes before cell lysate collection.
Immunoprecipitation and Western blot analysis. For immunopre-
cipitation of overexpressed WT and mutant EPHB4, transfected cells 
were harvested in 100 μl of lysis buffer (20 mM Tris pH 7.5, 150 mM 
NaCl, 0.5%Triton X-100) supplemented with protease and phospha-
tase inhibitors (Sigma-Aldrich). After clarification by centrifugation, 
100 μg of total HEK293T cell protein lysate was incubated with 0.8 μg 
of goat anti-human EPHB4 antibody (AF3038, R&D Systems) over-
night at 4°C. After incubation with protein A sepharose beads (Sigma-
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For analysis of LVVs, 100-μm coronal vibratome sections of E13.5 
embryos were cut and stained as described above. Single-plane images 
of the valve were taken where the valve was clearly visible. Only valves 
that appeared to be intact were included in the classification. Five 
control embryos (Ephb4fl/+ Prox1-CreERT2+ R26-mTmG+ and Ephb4+/+ 
Prox1-CreERT2+ R26-mTmG+) were cut, and 11 valves were imaged and 
included in the quantification. For mutant embryos (Ephb4fl/fl Prox1-
CreERT2+ R26-mTmG+), 13 valves from 9 embryos were imaged.
Image acquisition. Stereomicroscope images were acquired using 
a Leica MZ16F fluorescence microscope with a Leica DFC420C cam-
era and Leica Microsystems software. Confocal images were acquired 
using a Zeiss LSM 780 confocal microscope and Zen 2009 software 
or a Leica SP8 confocal microscope and Leica Application Suite X 
software. Images shown in Figure 5, C and D, were acquired as 4 × 2 
tile scans with a HCX PL APO CS ×10/0.40 dry objective. Images in 
Figure 6 were acquired using a Fluotar VISIR ×25/0.95 water objec-
tive. Images in Supplemental Figure 4A were taken with a HC PL APO 
CS2 63×/1.30 GLYC objective; images in Supplemental Figure 4B (P6 
mesentery) were taken using a C-Aphochromat ×40/1.20 W Korr M27 
objective, and images in Supplemental Figure 4, B (E18 mesentery), 
C, and D, were acquired using a Plan-Apochromat ×20/0.8 Ph2. All 
confocal images represent maximum intensity projections of z-stacks 
except images in Figure 6.
Lymphoscintigraphy. Lymphoscintigraphy is the imaging of the 
lymphatic system by injecting radioactive isotope (technetium-99m) 
into the web spaces between the toes and/or fingers and quantification 
of uptake into the inguinal lymph nodes for foot injections and axillary 
nodes for hand injection after 2 hours with a gamma camera.
Statistics. P values representing differences in the proportion of 
edematous and nonedematous mutant versus control littermates (Fig-
ure 5B) and the proportion of normal and abnormal LVVs (Figure 6D) 
were calculated using χ2/Fisher’s exact test (2-tailed). A P value of less 
than 0.05 was considered significant.
Study approval. Subjects in this study were recruited through 
genetic and lymphovascular clinics in Norway and the UK. Ethical 
approval for this study was obtained from the Norwegian Regional 
Committees for Medical and Health Research Ethics and the West 
(REC ref: 2011/2453) and South West London Research Ethics Com-
mittee (REC Ref: 05/Q0803/257). Written, informed consent was 
obtained for all subjects. All affected individuals and family mem-
bers underwent a detailed physical examination. Animal studies 
were approved by the UK Home Office and the Uppsala Laboratory 
Animal Ethical Committee.
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Aldrich) for 4 hours at 4°C, immune complexes were precipitated by 
centrifugation. 100 μl of total LEC protein lysate was incubated with 
4 μg of mouse anti-DDK antibody (clone OTI4C5, TA50011, Origene) 
overnight at 4°C and immune complexes precipitated with protein G 
sepharose beads (Sigma-Aldrich). Immunoprecipitates were separat-
ed by SDS-PAGE and transferred to PVDF membranes. Immunoblot 
analysis was performed with goat anti-human EPHB4 (AF3038, R&D 
Systems) and mouse anti-phosphotyrosine (clone 4G10, 05-321, Mil-
lipore) antibodies. All uncropped Western blots are shown in Supple-
mental Figures 6 and 7.
Mouse lines. We generated Ephb4fl/fl Prox1-CreERT2 R26-mTmG 
mice as follows: R26-mTmG mice were acquired from the Jackson 
Laboratory (36). Prox1-CreERT2 mice were previously described (17). 
For the generation of the Ephb4fl line, a conditional KO strategy, flank-
ing Ephb4 exons 2 and 3 with LoxP sites, was used to target the Ephb4 
locus. The targeting vector was built using homologous recombination 
in bacteria (37). A C57BL/6 mouse BAC served as a template for the 
extraction of the homology arms of the targeting vector. The target-
ing vector contained a frt flanked neomycin phosphotransferase (Neo) 
selectable marker cassette. After linearization, the targeting construct 
was electroporated into AZX1, a C57BL/6JOlaHsd-derived embry-
onic stem cell line. PCR screens and Southern blot analyses revealed 
clones that had undergone the desired homologous recombination 
event. Several of these clones were expanded and injected into BALB/
cOlaHsd blastocysts to generate chimeric males that were then bred to 
C57BL/6JOlaHsd females. Black-coated offspring were genotyped on 
both sides of the homology arms for correct integration into the EphB4 
locus. The Neo selectable marker cassette, which was flanked by frt 
sites, was deleted after subsequent breeding to mice expressing flp 
recombinase under the CAG promoter.
For embryonic induction of Cre recombination, 4-OHT (Sigma-
Aldrich) was dissolved in peanut oil (10 mg/ml). 1 mg was adminis-
tered to pregnant females by intraperitoneal injection at the indicated 
developmental stages. For induction during early postnatal develop-
ment, mice were administered at P1 and P2 with 50 μg of 4-OHT dis-
solved in ethanol by intraperitoneal injection. All strains were main-
tained and analyzed on a C57BL/6J background.
Immunofluorescence. For whole-mount immunostaining, tissues 
were fixed in 4% paraformaldehyde (PFA) for 2 hours at room tem-
perature, followed by permeabilization in 0.3% Triton X-100 PBS 
(PBSTx) and blocking in PBSTx 3% milk. Primary antibodies were 
incubated at 4°C overnight in blocking buffer. After washing several 
times, the samples were incubated with fluorochrome-conjugated 
secondary antibodies in blocking buffer for 2 hours before further 
washing and mounting in Mowiol. The following primary antibod-
ies were used: goat anti-mouse Ephb4 (AF446, R&D Systems), goat 
anti-human VE-cadherin (sc-6458, Santa Cruz Biotechnology Inc.), 
rabbit anti-human Prox1 (generated against human PROX1 C ter-
minus; 567–737 aa), rabbit anti-GFP (A11122, Invitrogen), chicken 
anti-GFP (Ab13970, Abcam), rat anti–PECAM-1 (553370, BD Bio-
sciences — Pharmingen), rat anti-endomucin (sc-65495, Santa 
Cruz Biotechnology Inc.) and rabbit anti-Lyve1 (103-PA50AG, Reli-
atech). Secondary antibodies conjugated to AF488, Cy3, or AF647 
were obtained from Jackson ImmunoResearch. Controls were lit-
termate embryos and mice of the following genotypes: Ephb4fl/+ 
Prox1-CreERT2+ R26-mTmG+, Ephb4fl/fl Prox1-CreERT2– R26-mTmG+, 
or Ephb4fl/fl Prox1-CreERT2– R26-mTmG–.
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